Tests cevostamab with pomalidomide and dexamethasone in previously treated multiple myeloma
Tests cevostamab plus pomalidomide and dexamethasone against standard care in adults with myeloma.
Plain-language title generated from the registry record
Registry title: Cevostamab in Combination With Pomalidomide and Dexamethasone Versus Standard of Care in Participants With Previously Treated Multiple Myeloma
Key facts
- Where
- Aarhus N, Copenhagen Oe, Roskilde, and Vejle, DenmarkSee the 4 sites
- Phase
- Phase 3
Where in Denmark
- Region MidtjyllandAarhus N, DenmarkTaking people
- RigshospitaletCopenhagen Oe, DenmarkTaking people
- Region SjaellandRoskilde, DenmarkTaking people
- Lillebaelt HospitalVejle, DenmarkTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Hoffmann-La Roche
- Trial code
- NCT07555938EU 2025-524028-23-00
- Record updated
- 10 November 2026
- Original description
The purpose of this study is to assess the efficacy and safety of cevostamab in combination with pomalidomide and dexamethasone (CevosPd) versus standard of care (SOC) in participants with multiple myeloma (MM) who have received one to three prior lines of therapy and have been exposed to an anti-CD38 monoclonal antibody (mAb) and lenalidomide.Read full original descriptionShow less
A Phase III, Randomized, Open-Label, Multicenter Study Evaluating the Efficacy and Safety of Cevostamab in Combination With Pomalidomide and Dexamethasone Versus Standard of Care in Patients With Multiple Myeloma Who Have Received One to Three Prior Lines of Therapy
The purpose of this study is to assess the efficacy and safety of cevostamab in combination with pomalidomide and dexamethasone (CevosPd) versus standard of care (SOC) in participants with multiple myeloma (MM) who have received one to three prior lines of therapy and have been exposed to an anti-CD38 monoclonal antibody (mAb) and lenalidomide.
Inclusion: Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1 at screening and immediately prior to start of administration of study treatment; Individuals with ECOG Performance Status of 2 solely due to local symptoms of myeloma (e.g., pain) are eligible; MM diagnosis according to the International Myeloma Working Group (IMWG) diagnostic criteria; Received one to three lines of prior therapy that included at least two consecutive cycles of either of the following: A regimen containing an anti-CD38 therapy, a regimen containing lenalidomide; Participants must have measurable disease during screening.
Exclusion: GI disease that might significantly alter absorption of oral drugs; Participants must not have any ongoing CNS disease or non-secretory myeloma; Known history of systemic light chain amyloidosis with major organ involvement (e.g., positive Congo Red stain or equivalent in tissue biopsy or documented within serum amyloid P component scan); Known history or current plasma cell leukemia.